TransMedics Group, Inc. (NASDAQ:TMDX) Stock Has Average Target Price of $115.60 According to Analysts

Shares of TransMedics Group, Inc. (NASDAQ:TMDX) have been assigned a consensus recommendation of “Hold” from the twelve brokerages that are covering the firm, MarketBeat.com reports. Seven research analysts have rated the stock with a hold rating and five have given a buy rating to the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $115.60.

Several research analysts recently commented on the stock. Piper Sandler reaffirmed an “overweight” rating and issued a $100.00 price target (down from $120.00) on shares of TransMedics Group in a research note on Wednesday, August 5th. Needham & Company LLC reissued a “buy” rating on shares of TransMedics Group in a research report on Friday, September 11th. UBS Group dropped their target price on shares of TransMedics Group from $80.00 to $77.00 and set a “neutral” rating on the stock in a research note on Wednesday, August 5th. Weiss Ratings upgraded shares of TransMedics Group from a “hold (c-)” rating to a “hold (c)” rating in a research note on Monday, August 31st. Finally, Barclays began coverage on shares of TransMedics Group in a research report on Wednesday, October 7th. They set an “overweight” rating and a $120.00 target price on the stock.

Insider Activity

In other news, Director David Weill acquired 1,336 shares of the company’s stock in a transaction that occurred on Friday, September 11th. The shares were bought at an average price of $81.63 per share, with a total value of $109,057.68. Following the completion of the purchase, the director directly owned 16,392 shares in the company, valued at $1,338,078.96. This trade represents a 8.87% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 6.90% of the company’s stock.

Institutional Investors Weigh In On TransMedics Group

A number of institutional investors and hedge funds have recently bought and sold shares of TMDX. Headlands Technologies LLC bought a new position in TransMedics Group in the second quarter worth approximately $1,634,000. The Manufacturers Life Insurance Company purchased a new stake in TransMedics Group during the second quarter worth $1,140,000. Candriam S.C.A. lifted its holdings in TransMedics Group by 45.4% during the first quarter. Candriam S.C.A. now owns 158,766 shares of the company’s stock worth $15,783,000 after buying an additional 49,580 shares during the period. Wellington Management Group LLP boosted its position in TransMedics Group by 6.1% during the 2nd quarter. Wellington Management Group LLP now owns 515,973 shares of the company’s stock valued at $34,271,000 after acquiring an additional 29,500 shares in the last quarter. Finally, FirstWave Capital Management LLC boosted its position in TransMedics Group by 53.9% during the 2nd quarter. FirstWave Capital Management LLC now owns 191,240 shares of the company’s stock valued at $12,702,000 after acquiring an additional 66,972 shares in the last quarter. 99.67% of the stock is owned by institutional investors.

TransMedics Group Stock Performance

TMDX stock opened at $68.98 on Friday. TransMedics Group has a twelve month low of $60.10 and a twelve month high of $156.00. The firm has a market cap of $2.38 billion, a price-to-earnings ratio of 17.73, a PEG ratio of 1.00 and a beta of 2.14. The business’s fifty day simple moving average is $79.68 and its two-hundred day simple moving average is $93.44. The company has a quick ratio of 6.07, a current ratio of 6.62 and a debt-to-equity ratio of 1.62.

TransMedics Group (NASDAQ:TMDX) last issued its earnings results on Thursday, November 5th. The company reported $0.51 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.30 by $0.21. The firm had revenue of $203.01 million during the quarter, compared to analyst estimates of $178.06 million. TransMedics Group had a net margin of 22.69% and a return on equity of 15.88%. The business’s revenue was up 41.1% on a year-over-year basis. During the same period in the previous year, the firm earned $0.66 earnings per share. Analysts predict that TransMedics Group will post 1.46 earnings per share for the current year.

Key TransMedics Group News

Here are the key news stories impacting TransMedics Group this week:

• Positive Sentiment: Revenue rose 41.1% year over year to $203.0 million, above analyst expectations of about $178 million. Adjusted quarterly earnings were $0.51 per share, also ahead of estimates of $0.27–$0.30. TransMedics Q3 2026 results
• Positive Sentiment: TransMedics increased its full-year 2026 guidance, citing strong revenue generation, and pointed to near- and mid-term growth catalysts. TransMedics Q3 2026 results
• Negative Sentiment: Quarterly EPS was below the $0.66 reported a year earlier, which may have tempered the positive impact of the revenue growth and estimate beat. Earlier commentary also highlighted margin pressure and rising investment needs as risks. Reasons to retain TransMedics stock

About TransMedics Group

TransMedics Group, Inc is a medical technology company focused on improving organ transplantation through systems that preserve and assess donor organs outside the body. The company’s primary platform is the Organ Care System (OCS), a portable, technology-enabled perfusion system designed to maintain organs in a functioning, near-physiologic state during transport and evaluation.

TransMedics offers OCS products for heart, lung and liver transplantation. Its systems are intended to support the use of organs that may not otherwise be suitable for conventional cold-storage methods, potentially expanding the donor pool and providing transplant teams with additional information when evaluating organs for transplantation.

Founded in 1998 and headquartered in Andover, Massachusetts, TransMedics serves transplant centers in the United States and select international markets.